Clinical trial NCT06741657: A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different Ways
Official title: A Randomized, Open-Label, 2-Arm, 2-Part, Parallel Group Study to Assess the Pharmacokinetic Comparability of Subcutaneously Administered Litifilimab (BIIB059) Delivered by 3 Devices (Pre-Filled Syringe, Autoinjector, or On-Body Injector) in Healthy Participants
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Healthy Volunteer
Lead sponsor: Biogen
Sponsor class: INDUSTRY
First posted: 2024-12-19
Enrollment: 236
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In this study, researchers will learn how the body processes litifilimab when it is given under the skin in 3 different ways. Currently, ongoing studies utilize pre-filled syringes (PFS) that can deliver litifilimab subcutaneously (SC), also known as under the skin.

In this study, researchers want to learn more about new ways of delivering litifilimab SC using either an autoinjector (AI) or an on-body injector (OBI):

Both devices are designed to deliver litifilimab in an automatic way, especially helping patients who may not be able to use their hands very well, or who may be afraid of needles. While the AI is handheld, the OBI device works by being placed on the skin and can help deliver the highest amount of litifilimab through a single injection. The main objective of this study is to learn how the body processes litifilimab after using the AI device or the OBI device, as compared to using the PFS method.

The main questions researchers want to answer are:

* What is the highest amount of litifilimab found in the blood after dosing? How much total litifilimab is found in the blood throughout the study? Researchers will also learn more about: Any medical problems the participants have during the study
* Any injection site pain or reactions the participants may have. Any skin reactions to the OBI device
* Any changes in the participants' overall health after receiving litifilimab.

This study will be done as follows:

* Participants will be screened to check if they can join the study. The screening period will be up to 4 weeks, after which selected participants will check into their study research center.
* Participants will be randomly assigned to be in Part 1 or Part 2 of the study:
* Part 1: Participants will receive SC injection(s) of litifilimab through either the AI device or through PFS.
* Part 2: Participants will receive SC injection(s) of litifilimab through the OBI device or through PFS.
* Participants will remain at their study research center for the first 8 days. After that, there will be a follow-up period for 17 weeks during which participants return to the center a total of 6 times.

Each participant will be in the study for about 22 weeks.

Detailed description: The primary objective of this study is to assess the pharmacokinetic (PK) comparability of litifilimab administered via SC injection(s) of AI (Test Device 1) or SC injection(s) of OBI (Test Device 2), with SC injections of PFS (Reference) in healthy participants.

The secondary objectives of this study are to evaluate the safety and tolerability following SC dose of litifilimab via AI, OBI, or PFS; to assess additional PK parameters following SC dose of litifilimab via AI, OBI, or PFS in healthy participants.

Eligibility criteria: Key Inclusion Criteria

* Must have a body mass index between 18.5 and 30 kilograms per square meter (kg/m\^2), and a body weight ≥ 50 kg to ≤ 100 kg.
* Must be in good health as determined by the investigator, based on medical history physical examination, electrocardiogram (ECG), and other screening evaluations.

Key Exclusion Criteria

* History of any clinically significant cardiac, endocrine, gastrointestinal, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, or renal disease, or other major disease, as determined by the investigator.
* A positive diagnostic tuberculosis test result within 4 weeks prior to Enrollment (Day 1), defined as a positive QuantiFERON® test result or 2 successive indeterminate QuantiFERON test results.
* History or positive test result for human immunodeficiency virus (HIV).
* History of severe herpes infection such as herpetic encephalitis, ophthalmic herpes, or disseminated herpes.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Primary outcomes:
measure: Part 1 and 2: Maximum Observed Concentration (Cmax) of Litifilimab
timeFrame: Pre-dose and at multiple timepoints up to Week 22
measure: Part 1 and 2: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf)
timeFrame: Pre-dose and at multiple timepoints up to Week 22
Secondary outcomes:
measure: Part 1 and 2: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
timeFrame: From screening up to Week 22
measure: Part 1 and 2: Change From Baseline in the Injection Site Pain as Measured by Patient Reported Outcome (PRO) Using a Pain Intensity Numeric Rating Scale (PI-NRS)
timeFrame: Baseline, Day 1
measure: Part 1 and 2: Percentage of Participants With Mild, Moderate, Severe, or no Injection Site Reactions
timeFrame: Up to Week 1
measure: Part 2: Percentage of Participants With Adhesive Contact Skin Reactions as Measured by Dermal Response and Other Effects Scales
timeFrame: Up to Week 1
measure: Part 1 and 2: Number of Participants With Change From Baseline in Clinically Significant Vital Signs Abnormalities
timeFrame: Baseline, up to Week 22
measure: Part 1 and 2: Number of Participants With Change From Baseline in Clinically Significant 12-Lead Electrocardiograms (ECGs) Abnormalities
timeFrame: Baseline, up to Week 4
measure: Part 1 and 2: Number of Participants With Change From Baseline in Clinically Significant Laboratory Evaluation Abnormalities
timeFrame: Baseline, up to Week 22
measure: Part 1 and 2: Number of Participants With Change From Baseline in Clinically Significant Physical Examination Abnormalities
timeFrame: Baseline, up to Week 22
measure: Part 1 and 2: Time to Reach Cmax (Tmax) of Litifilimab
timeFrame: Pre-dose and at multiple timepoints up to Week 22
measure: Part 1 and 2: Terminal Elimination Half-life (t1/2) of Litifilimab
timeFrame: Pre-dose and at multiple timepoints up to Week 22
measure: Part 1 and 2: Apparent Total Clearance (CL/F) of Litifilimab
timeFrame: Pre-dose and at multiple timepoints up to Week 22
measure: Part 1 and 2: Volume of Distribution (Vd/F) of Litifilimab
timeFrame: Pre-dose and at multiple timepoints up to Week 22
measure: Part 1 and 2: Area Under the Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUC0-last) of Litifilimab
timeFrame: Pre-dose and at multiple timepoints up to Week 22
Other outcomes:
Locations:
city: Las Vegas
country: United States
facility: Las Vegas Clinical Research Unit
state: Nevada
city: Austin
country: United States
facility: Austin Clinical Research Unit
state: Texas
Study officials:
affiliation: Biogen
name: Medical Director
role: STUDY_DIRECTOR
References: